文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

接受抗逆转录病毒治疗的HIV感染者停用复方新诺明后疟原虫血症与密度的变化

Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
PubMed 文献 · J Infect Dis · 2016-10-25

本研究对500名接受抗逆转录病毒治疗的HIV感染者进行随机试验,比较继续与停用复方新诺明(CTX)后疟原虫血症情况。停用CTX组疟原虫血症患病率随时间逐渐升高,12个月时达22%,而继续CTX组为4%;停用组发病率是继续组的4.3倍(95%CI 2.7-7.1),且混合感染仅见于停用组。

要点

  • 停用复方新诺明后疟原虫血症患病率与密度均逐渐升高。
  • 停用组疟疾发病率42.0例/100人年,继续组9.9例/100人年,IRR 4.3。
  • 混合感染仅出现在停用复方新诺明组。

核心结论

  • 接受抗逆转录病毒治疗的HIV感染者停用复方新诺明会导致疟原虫血症患病率和负担逐渐增加。

研究设计与样本

  • 一项随机试验,纳入500名接受抗逆转录病毒治疗的HIV感染者,随机分为继续复方新诺明组和停用组。
  • 通过定量逆转录聚合酶链反应检测疟原虫,在入组时、之后每3个月共12个月及就诊时采集标本。

主要发现

  • 基线时5%的感染者可检测到疟原虫血症。
  • 随机分组后,停用组疟原虫患病率随时间增加,第3、6、9、12个月分别为4%、8%、14%、22%,而继续组分别为<1%、2%、2%、4%(P = .0034)。
  • 各时间点合并平均疟原虫密度停用组更高(4.42 vs 3.13 log10 parasites/mL;P < .001)。
  • 疟原虫血症发病率停用组为42.0例/100人年,继续组为9.9例/100人年,发病率比为4.3(95%CI 2.7-7.1;P < .001)。
  • 入组后混合感染(感染多重度>1)仅见于停用组。

关键数值与推荐

  • 停用复方新诺明组第12个月疟原虫血症患病率为22%,继续组为4%(P = .0034)。
  • 停用组疟疾发病率42.0例/100人年,继续组9.9例/100人年,发病率比4.3(95%CI 2.7-7.1;P < .001)。

临床怎么用

  • 对于接受抗逆转录病毒治疗的HIV感染者,停用复方新诺明前应评估疟疾风险,并考虑监测或预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cotrimoxazole (CTX) discontinuation increases malaria incidence in human immunodeficiency virus (HIV)-infected individuals. Rates, quantity, and timing of parasitemia rebound following CTX remain undefined. METHODS: Serial specimens from a trial of HIV-infected individuals receiving antiretroviral treatment (ART) randomized to continue (the CTX arm) or discontinue (the STOP-CTX arm) were examined for malaria parasites by quantitative reverse transcription polymerase chain reaction (PCR). Specimens obtained at enrollment and then quarterly for 12 months and at sick visits were assessed; multiplicity of infection was evaluated by PCR that targeted the polymorphic msp-1/msp-2 alleles. RESULTS: Among 500 HIV-infected adults receiving ART (median ART duration, 4.5 years), 5% had detectable parasitemia at baseline. After randomization, parasite prevalence increased over time in the STOP-CTX arm, compared with the CTX arm, with values of 4% and <1%, respectively, at month 3, 8% and 2% at month 6, 14% and 2% at month 9, and 22% and 4% at month 12 (P = .0034). The combined mean parasite density at the various time points was higher in the STOP-CTX arm (4.42 vs 3.13 log10 parasites/mL; P < .001). The parasitemia incidence was 42.0 cases per 100 person-years in the STOP-CTX arm and 9.9 cases per 100 person-years in the CTX arm, with an incidence rate ratio of 4.3 (95% confidence interval, 2.7-7.1; P < .001). After enrollment, mixed infections (multiplicity of infection, >1) were only present in the STOP-CTX arm. CONCLUSION: Discontinuation of CTX by HIV-infected adults receiving ART resulted in progressive increases in malaria parasitemia prevalence and burden. CLINICAL TRIALS REGISTRATION: NCT01425073.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ottichilo RK, Polyak CS, Guyah B, et al. Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis. J Infect Dis. 2016. PMID: 28077587. doi:10.1093/infdis/jiw495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。